OMEROS CORP

EMA rejects Omeros’ Narsoplimab, slashing EU prospects; U.S. sales & Medicare code boost resilience—what’s next for the biotech stock?

Omeros Corp’s breakthrough in TA‑TMA therapy and growing MASP‑2 pipeline, backed by Novo Nordisk funding, position it for a 2026 EMA win and global expansion.

Omeros Corp’s breakthrough TA‑TMA therapy and EMA review of Narsoplimab could double its patient market, driving global growth and investor interest.

Omeros Corp. completes primate study for OncotoX‑AML™—a critical step toward targeted AML therapy, boosting investor interest amid volatile biotech markets.

Omeros Corp (OMRS) – Seattle‑based biotech developing orthopedics, rheumatology, urology and cardiovascular drugs. Despite a 23% year‑to‑date decline, it remains focused on innovation across 6 therapeutic areas.

Omeros Corp’s Yartemlea receives historic FDA approval for HSCT patients, positioning the company as a leader in transplant‑associated TA‑TMA therapy and boosting its revenue outlook.

Omeros’ stock jumps after FDA approval of YARTEMLEA®, the first therapy for transplant‑associated thrombotic microangiopathy – a rare, life‑threatening complication.

Omeros’ FDA approval of YARTEMLEA® turns a biotech risk‑maker into a revenue generator, driving a 100% share surge and unlocking high‑price specialty therapy opportunities.

Omeros Corp’s diversified pipeline—from orthopedics to pain management—offers a rare chance for upside amid pharma’s market turmoil, with investors watching key clinical milestones.

Omeros Corp, a Seattle-based biopharmaceutical company, is preparing to announce its second-quarter financial results on August 14, 2025, amidst market fluctuations and investor anticipation.